rhIGF-I administration in humans: Differential metabolic effects of bolus vs. continuous subcutaneous delivery

American Journal of Physiology - Endocrinology and Metabolism

Volumn 272, Issue 4 35-4, 1997, Pages

  Mauras, Nelly ^a   Martha Jr , Paul M ^b   Quarmby, Valerie ^b   Haymond, Morey W ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b GENENTECH INC   (United States)

Author keywords

free insulin like growth factor I; glucose metabolism; lipid metabolism; protein metabolism

Indexed keywords

SOMATOMEDIN C;

ADULT; ARTICLE; BODY MASS; CONTINUOUS INFUSION; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIPID METABOLISM; LIPID OXIDATION; MALE; METABOLIC REGULATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS REGULATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031001621     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1997.272.4.e628     Document Type: Article

References (34)

1. Bier, D. M., R. D. Leake, M. W. Raymond, K. J. Arnold, L. D. Gruenke, M. A. Sperling, and D. M. Kipnis. Measurement of "true" glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes 26: 1016-1023, 1977.
2. Clemmons, D. R., A. Smith-Banks, and L. E. Underwood. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J. Clin. Endocrinol. Metab. 75: 234-238, 1992.
3. Copeland, K. C., F. A. Kenney, and K. S. Nair. Heated dorsal hand vein sampling for metabolic studies: a reappraisal. Am. J. Physiol. 263 (Endocrinol. Metab. 26): E1010-E1014, 1992.
4. Daughaday, W. H., I. K. Mariz, and S. L. Blethen. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J. Clin. Endocrinol. 51: 781-788, 1980.
5. Davenport, M. L., W. L. Isley, J. B. Pucilowska, L. B. Pemberton, B. Lyman, L. E. Underwood, and D. R. Clemmons. Insulin-like growth factor binding protein-3 proteolysis is induced after elective surgery. J. Clin. Endocrinol. Metab. 75: 590-595, 1992.
6. Davies, S. C. C., J. H. Wass, R. J. M. Ross, A. M. Cotterill, C. R. Buchanan, and J. M. Holly. The induction of a specific protease for insulin-like growth factor binding protein 3 in the circulation during severe illness. J. Endocrinol. 130: 469-473, 1991.
7. Ferranini, E. The theoretical bases of indirect calorimetry: a review. Metabolism 37: 287-301, 1988.
8. Fryburg, D. A. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am. J. Physiol. 267 (Endocrinol. Metab. 30): E331-E336, 1994.
9. Frystyk, J., K. Skjaerbaek, B. Dinesen, and H. Orskov. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348: 185-191, 1994.
10. Guler, H. P., J. Zapf, and E. R. Froesch. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 317: 137-140, 1987.
11. Horber, F. F., and M. W. Haymond. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J. Clin. Invest. 86: 265-272, 1990.
12. Horber, F. F., C. M. Horber-Feyder, S. Krayer, W. F. Schwenk, and M. W. Haymond. Plasma reciprocal pool specific activity predicts that of intracellular free leucine for protein synthesis. Am. J. Physiol. 257 (Endocrinol. Metab. 20): E385-E399, 1989.
13. Hussain, M. A., O. Schmitz, A. Mengel, Y. Glatz, J. S. Christiansen, J. Zapf, and E. R. Froesch. Comparison of the effects of GH and IGF-I on substrate oxidation and on insulin sensitivity in GH-deficient humans. J. Clin. Invest. 94: 1126-1133, 1994.
14. Johnston, B. M., E. C. Mallard, C. E. Williams, and P. D. Gluckman. Insulin-like growth factor-I is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. J. Clin. Invest. 97: 300-308, 1996.
15. Lewis, M. E., N. T. Neff, P. C. Contreras, D. B. Strong, R. W. Oppenheim, P. E. Grebow, and J. L. Vaught. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol. 124: 73-88, 1993.
16. Lieberman, S. A., J. Bukar, S. A. Chen, A. C. Celniker, P. G. Compton, J. Cook, A. J. Perlman, and A. R. Hoffman. Effects of recombinant human insulin-like growth factor I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. J. Clin. Endocrinol. Metab. 75: 30-36, 1992.
17. Lieberman, S.A., G. E. Butterfield, D. Harriwon, and A. R. Hoffman. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 78: 404-410, 1994.
18. Mauras, N., and B. Beaufrere. rhIGF-I enhances whole body protein anabolism and significantly diminishes the protein-catabolic effects of prednisone in humans, without a diabetogenic effect. J. Clin. Endocrinol. Metab. 80: 869-874, 1995.
19. Mauras, N., F. F. Horber, and M. W. Haymond. Low dose recombinant human insulin-like growth factor I fails to affect protein anabolism but inhibits islet cell secretion in humans. J. Clin. Endocrinol. Metab. 75: 1192-1197, 1992.
20. Miell, J. P., A. M. Taylor, J. Jones, C. R. Buchanan, J. Rennie, R. Sherwood, R. Leicester, and R. J. Ross. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin. Endocrinol. 37: 542-551, 1992.
21. Miller, S. B., M. Moulton, M. O'Shea, and M. R. Hammerman. Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int. 46: 201-207, 1994.
22. Nakagawa, S., H. Nakayama, T. Sasaki, K. Yoshino, and Y. Y. Yu. A simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22: 590-600, 1973.
23. Nissen, S., and M. W. Haymond. Changes in leucine kinetics during meal absorption: effects of dietary leucine availability. Am. J. Physiol. 250 (Endocrinol. Metab. 13): E695-E701, 1986.
24. Non-Insulin-Dependent Diabetes Study Group (RINDS). Recombinant insulin-like growth factor I (rhIGF-I) treatment of non-insulin dependent diabetes mellitus (NIDDM): effects of gender and prior hypoglycemic therapy (Abstract). Diabetes 45: 55, 1996.
25. Rosen, C. J., L. R. Donahue, and S. J. Hunter. Insulin-like growth factors and bone: the osteoporosis connection. Proc. Soc. Exp. Bio. Med. 206: 83-102, 1994.
26. Rosenbloom, A. L., J. Guevara-Aguirre, R. G. Rosenfeld, and B. H. Pollock. Growth in growth hormone insensitivity. Trends Endocrinol. Metab. 5: 296-303, 1994.
27. Schoenle, E., J. Zapf, R. E. Humbel, and E. R. Froesch. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296: 252-253, 1982.
28. Takada, M., H. Nakanome, M. Kishida, S. Hirose, and Y. Hasegawa. Measurement of free insulin-like growth factor-I using immunoradiometric assay. J. Immunoassay 15: 263-276, 1994.
29. Tappy, L., N. Paquot, P. Tounian, P. Schneiter, and E. Jequier. Assessment of glucose metabolism in humans with simultaneous use of indirect calorimetry and tracer techniques. Clin. Physiol. 15: 1-12, 1995.
30. Tomas, F. M., S. E. Knowles, C. S. Chandler, G. L. Francis, P. C. Owens, and F. J. Ballard. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J. Endocrinol. 137: 413-421, 1993.
31. Turkalj, I., U. Keller, R. Ninnis, S. Vosmeer, and W. Stauffacher. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J. Clin. Endocrinol. Metab. 75: 1186-1191, 1992.
32. Tzannis, S. T., W. J. M. Hrusheski, P. A. Wood, and T. M. Przybycien. Irreversible inactivation of interleucin 2 in a pump-based delivery environment. Proc. Natl. Acad. Sci. USA 93: 5460-5465, 1996.
33. Zapf, J., E. Schoenle, M. Waldrogel, I. Sand, and E. R. Froesch. Effect of trypsin treatment on rat adipocytes on biological effects and binding of insulin and IGFs: further evidence for the action of IGFs through the insulin receptor. Eur. J. Biochem. 113: 605-609, 1981.
34. Zenobi, P. D., S. E. Jaeggi-Groisman, W. F. Riesen, M. E. Roder, and E. R. Froesch. Insulin-like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus. J. Clin. Invest. 90: 2234-2241, 1992.